Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients

Int J Cancer. 1994 Jul 1;58(1):20-3. doi: 10.1002/ijc.2910580105.

Abstract

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have recently been introduced in the treatment of chemotherapy-induced neutropenia. Effects of these CSFs on the cellular immune system were evaluated in 38 neutropenic gynecological cancer patients during chemotherapy. In addition to restoring the leukocyte count, GM-CSF--to a greater extent than G-CSF--also induced neopterin, a sensitive marker of macrophages activated by interferons. This effect was confirmed in vitro by investigating the effects of these CSFs on interferon-gamma-mediated pathways in THP-I human myelomonocytic cells. The results suggest activation of immune effector cells by GM-CSF.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / biosynthesis*
  • Biomarkers, Tumor / urine
  • Biopterins / analogs & derivatives*
  • Biopterins / biosynthesis
  • Biopterins / urine
  • Cell Line
  • Female
  • Genital Neoplasms, Female / drug therapy*
  • Genital Neoplasms, Female / immunology*
  • Genital Neoplasms, Female / metabolism
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Immunity, Cellular / drug effects
  • Leukocyte Count / drug effects
  • Middle Aged
  • Neopterin

Substances

  • Biomarkers, Tumor
  • Granulocyte Colony-Stimulating Factor
  • Biopterins
  • Neopterin
  • Granulocyte-Macrophage Colony-Stimulating Factor